New Zealand breast density software Volpara Solutions has made its first sale into India as the technology continues its rapid global expansion, now in 31 countries and with revenues doubling year on year.
In a NZ$100,00 deal, Volpara Solutions – developed by Wellington-based company Matakina Technology – has been purchased by the Post Graduate Institute of Medical Education and Research (PGIMER) in Chandigarh for research purposes.
“This is an important first sale into such a major global economy with a massive population and rising incidence of breast cancer which our software can help understand and hopefully reverse,” says CEO of Volpara Solutions Ralph Highnam.
India’s National Cancer Registry Programme reports a rising incidence of breast cancer in younger patients, which some medical professionals attribute to the increase to lifestyle changes including rapid urbanisation and women marrying later, delaying childbirth.
High breast density increases cancer risk by four to six times compared to low breast density, and PGIMER will use the software to better understand why India’s cancer risk is rising, and the differences in cancer risk between their different ethnic populations.
“Volpara Solutions is readily scalable, able to be deployed anywhere in the world where we have regulatory clearance so is readily-accessible for PGIMER to gather and analyse this critical data on breast health in their population,” Highnam says.
The sale into India follows Volpara Solutions’ new installations recently completed in Belgium, Canada, Turkey, Korea, Japan and the United Kingdom. Volpara Solutions technology is now in use in 31 countries and more than four million women have had their breast density analysed using VolparaDensity.
Volpara Solutions was also adopted in December 2014 by global giant GE Healthcare as a complementary solution with its medical equipment, massively increasing the software’s potential global market.